CLOVIS ONCOLOGY Forum: Community User: Maroni

liegen lassen oder. ..?

dito

top

Nähere mich langsam wieder dem EK :)

sieht weiterhin gut aus...

Und Ende Juni gibt's News zu Ruca.. Dann hoffentlich Rakete

nee nee..zumal ohne news

Bloß nicht euphorisch werden, es kann jederzeit wieder korrigieren. Aber die Tendenz stimmt wieder...

wenn es über 14 geht sieht es gut aus oder?!?!?

Endlich mal ein aufwärts-Trend

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced its presence at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, where it will share updated results from clinical studies of rucaparib. ASCO will take place June 3-7, 2016 in Chicago. “We look forward to providing updates on rucaparib data in ovarian cancer, including in patients with mutations beyond BRCA, as well as the first presentation of our pancreatic cancer data,” said Patrick J. Mahaffy, CEO and President of Clovis Oncology. “These datasets demonstrate rucaparib’s encouraging clinical activity and tolerability profile in the treatment of ovarian and pancreatic cancers. Both represent diseases in which BRCA mutations play a significant role in certain patients, as well as areas where additional treatment options are very much needed.”

Ja nicht gut aber schon eingepreist? zum Schluss steht das Erkenntnisse daraus gezogen wurde. ..mmhh...ist auch mehrdeutig zu verstehen

Enrollment was stopped due to lack of responses in the first 15 pts evaluated; the 3 PRs occurred in the last 4 pts enrolled. Common treatment-related AEs included nausea and anemia (37% each). Common treatment-related grade ≥ 3 AEs included anemia (26%), thrombocytopenia (16%), and fatigue (11%).Conclusions: Rucaparib provided clinical benefit to pts with advanced PC and a BRCA mutation and demonstrated an acceptable safety profile. Less heavily pretreated pts derived durable benefit, suggesting that rucaparib may be an option earlier in the treatment course. These findings may inform future study designs in pts with advanced PC. Clinical trial information: NCT02042378

Nachzulesen hier: http://abstracts.asco.org/176/AbstView_176_166810.html

Oh oh... Nicht so gut glaub ich: “Rucaparib in panc enrollment stopped due to lack of response in 1st 15 pats“

Bei mir ist nix mit Zock.. Da ist alles tief dunkel rot :-)